# Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Study · id `cardio:ct-nct02836704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02836704](<https://clinicaltrials.gov/study/NCT02836704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02836704

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.

## Technical summary

Registry record NCT02836704. Randomized; no masking; primary purpose treatment. Start 2016-09-09 (actual); primary completion 2018-04-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 892 participants (enrolled count; ClinicalTrials.gov record NCT02836704, source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)
- Started: 2016-09-09 (actual) (ClinicalTrials.gov record NCT02836704, source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2018-04-26 (actual) (ClinicalTrials.gov record NCT02836704, source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)
- Completion: 2018-04-26 (actual) (ClinicalTrials.gov record NCT02836704, source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02836704, source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02836704-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): INSULIN GLARGINE
- Intervention (Drug): metformin
- Intervention (Drug): acarbose
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: c94926d675ec3d5ae150471faabd53221b440cb360848ed48c5bfeddbbe6ab78
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
